YJEFN3: A Potential Drug Target and Biomarker (G374887)

Target Name: YJEFN3

NCBI ID: G374887

YJEFN3

YJEFN3: A Potential Drug Target and Biomarker

YJEFN3, also known as hYjeF-N3, is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. Its function and structure have been well-studied, and it has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, diabetes, and cancer.

Potential Drug Target

YJEFN3 is a protein that is involved in various signaling pathways in the brain, including the TGF-β pathway. This pathway is known to be involved in the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. YJEFN3 has been shown to play a role in the regulation of this pathway, and it is possible that targeting it could be a effective way to treat these disorders.

In addition to its role in the TGF-β pathway, YJEFN3 has also been shown to be involved in the regulation of various other signaling pathways, including the Wnt pathway, the Notch pathway, and the FGF pathway. These pathways are involved in various cellular processes that are important for the development and maintenance of tissues and organs, and targeting them may be a promising way to treat a variety of diseases.

Biomarker

In addition to its potential as a drug target, YJEFN3 has also been identified as a potential biomarker for several diseases. For example, it has been shown to be involved in the development of neurodegenerative disorders, and levels of YJEFN3 have been shown to be decreased in individuals with these disorders. This suggests that targeting YJEFN3 could be a promising way to diagnose and treat these disorders.

In addition to its potential as a drug target and biomarker, YJEFN3 is also of interest to researchers because of its structure and function. Its protein sequence is highly conserved across various species, and its structure suggests that it has a unique fold that is involved in its function. This unique fold has been shown to be involved in the regulation of various cellular processes, and researchers are interested in studying its mechanisms of action.

Conclusion

In conclusion, YJEFN3 is a protein that has potential as a drug target and biomarker for various diseases. Its function and structure suggest that it is involved in various signaling pathways in the brain, and its potential as a drug target is based on its involvement in the TGF-β pathway and other signaling pathways. Further research is needed to fully understand its mechanisms of action and its potential as a drug and biomarker.

Protein Name: YjeF N-terminal Domain Containing 3

Functions: May accelerate cholesterol efflux from endothelial cells to high-density lipoprotein (HDL) and thereby regulates angiogenesis. May orchestrate hematopoietic stem and progenitor cell emergence from the hemogenic endothelium, a type of specialized endothelium manifesting hematopoietic potential. YJEFN3-mediated cholesterol efflux activates endothelial SREBF2, the master transcription factor for cholesterol biosynthesis, which in turn transactivates NOTCH and promotes hematopoietic stem and progenitor cell emergence (By similarity). May play a role in spermiogenesis and oogenesis (PubMed:17533573)

The "YJEFN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YJEFN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets